A Tough Road Ahead for This Big Pharma Partner: Codexis, Inc. (CDXS), Royal Dutch Shell plc (ADR) (RDS.A)

Page 1 of 2

Bio-based enzyme producer Codexis, Inc. (NASDAQ:CDXS) reported financial results for the fourth quarter and full-year 2012 last week. How did things go? Well, the company was clearly set back after Royal Dutch Shell plc (ADR) (NYSE:RDS.A) axed a partnership between the two earlier in the year. What was more surprising for investors was the pullback in pharmaceutical revenue, which is by far the company’s most mature revenue stream. Is all hope lost for this once-promising sustainable chemical enabler?

Royal Dutch Shell plc (ADR) (NYSE:RDS-A)Financials
Here are the dismal results:

4Q12 4Q11 2012 2011
Product sales $6.83 $15.49 $35.92 $49.02
Total revenue $7.91 $33.49 $88.3 $123.86
Total expenses $23.66 $38.40 $118.81 $139.77
Net loss $15.54 $5.30 $30.86 $16.55

Source: Codexis, all figures in millions.

It doesn’t take many calculations to see that Codexis, Inc. (NASDAQ:CDXS) had a lousy year without Royal Dutch Shell plc (ADR) (NYSE:RDS.A)’s deep pockets, which provided the bulk of revenue in years past. After a series of cost reduction steps by a transformed management team, Codexis had to focus its limited capital and personnel on core areas. Even that didn’t help a big drop in pharmaceutical revenue, which was not spared from restructuring.

A few bright spots include ending the year with more cash than anticipated ($49 million) and several small partnerships for enzyme kits, which management believes can make up an important revenue stream in the next few years. Unfortunately for investors hoping that Codexis, Inc. (NASDAQ:CDXS) would turn a corner and post a profit sooner rather than later, the company’s plans have encountered a serious setback.

Outlook
Management is guiding for pharmaceutical revenue between $35 million and $40 million. Codexis will also focus on higher-margin enzymes, rather than pharmaceutical intermediates, to boost total gross product margin from 15% last year to between 30% and 35% this year. For instance, a recent deal with Arch Labs calls for Codexis to provide enzymes while its partner will provide the intermediates. Still, without a strategic partner on board, the company expects to burn between $12 million and $16 million for the year.

Several small royalty streams will help boost pharmaceutical sales. After receiving FDA approval for a new production process, Merck & Co., Inc. (NYSE:MRK) will begin biomanufacturing sitagliptin with pharmaceutical intermediates supplied by Codexis. Sitagliptin is the active pharmaceutical ingredient in the blockbuster diabetes franchise Januvia/Janumet, which had $5.75 billion in worldwide sales in 2012. The companies also work together to produce Victrelis, a potential blockbuster hepatitis C drug.

Codexis will also receive a milestone payment and recurring royalties from Exela Pharma and Hikma Pharmaceuticals, which had its argatroban injection approved by the FDA. Management admitted that while the company’s products will still enable the production of generic drugs, they will increasingly focus on innovator drugs due to a focus on margins.

The company will complete its CodeXol Detergent Alcohol pilot plant in Rivalta, Italy, in the first half of the year. On the conference call, CEO John Nichols said that Codexis’ strains “approximately meet” industry specifications for products. Landing a consumer products partner will depend on actual results, but the absence of a partner thus far may speak for itself.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Countries with the Highest Suicide Rates

The 10 Most Technologically Advanced Countries in the World

The 10 Safest Countries in the World to Live in Peace

The 10 Top Selling Smartphones in the World 2014

The 12 Biggest Shopping Centers in the World

The 10 Friendliest Countries in the World

Qihoo 360 Technology Co Ltd (QIHU), Actavis plc (ACT), Yahoo! Inc. (YHOO) Among 20 Long Ideas from Sohn Canada

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!